linjc16/ctgov huggingface dataset:
Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone

Study Overview
=================
Brief Summary
-----------------
The planned study has two purposes: It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .

Official Title
-----------------
Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone

Conditions
-----------------
Elderly

Intervention / Treatment
-----------------
* Drug: Donepezil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 70 and 80 years Exclusion Criteria: Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block), Treatment with beta-blockers, NSAIDs or cholinergic agonists, Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any excipients used in the formulation, Gastric and duodenal ulcer, Severe renal and hepatic impairment, Urinary congestion (prostatic hypertrophy), Obstructive pulmonary disease (bronchial asthma);

Ages Eligible for Study
-----------------
Minimum Age: 70 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum IGF1 |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth hormone, body composition variables |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aging
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer who were treated with intensive chemotherapy for prevention of neutrophil reduction.

Conditions
-----------------
Breastcancer

Intervention / Treatment
-----------------
* Drug: PEG-rhG-CSF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.18-65 years old, gender no limited. 2.Breast cancer diagnosed by pathology. 3.Did not receive chemotherapy previously and plans to receive 4 cycles intensive EC (epirubicin, cyclophosphamide) treatment. 4.No obvious blood system disease, ANC(absolute neutrophil count)≥ 1.5 × 10^9/L, PLT（Platelet）≥80×10^9 /L, Hb（hemoglobin）≥75g/L, WBC（White blood cell ）≥3×109/L, and no bleeding tendency. 5.KPS (Karnofsky performance status) score≥70. 6.Expected survival≥3 months. 7.Written informed consent are acquired. Exclusion Criteria: Severe or uncontrolled infection. Sensitive to the product or other genetically engineered biological products from Escherichia coli strains. Mental or nervous system disorders. Severe heart, lung and central nervous system disorders. Pregnant or lactating women. TBIL(total bilirubin ), ALT（alanine aminotransferase）,AST（glutamic-oxalacetic transaminase） > 2.5×ULN（upper limit of normal）; if it were caused by liver metastases, TBIL, ALT,AST >5×ULN. Cr（creatinine） >1.5×ULN.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PEG-rhG-CSF<br>Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF. | Drug: PEG-rhG-CSF<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of chemotherapy delay |  | 60 days after the first chemotherapy |
Surfactant Administration in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
In preterm infants with respiratory distress syndrome, mechanical ventilation is related to increased risk of death and complications. Surfactant is an important methods to reduce mortality and intubation rates. INSURE technique is a standard method to administrate surfactant. However, several preterm infants need two or more surfactant, and therefore one more intubation is needed. How to reduce the times of intubation is an challenges for neonatologists.

Detailed Description
-----------------
INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant. The differences of modified INSURE compared with INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.

Official Title
-----------------
Modified INSURE vs INSURE in Preterm Infants With Respiratory Distress Syndrome: A Randomized Controlled Trials

Conditions
-----------------
Modified INSURE Technique

Intervention / Treatment
-----------------
* Other: Modified INSURE technique
* Other: INSURE technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All preterm infants with respiratory distress syndrome Exclusion Criteria: congenital abnormalities or refuse the trials

Ages Eligible for Study
-----------------
Maximum Age: 6 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Modified INSURE<br>Modified INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving. | Other: Modified INSURE technique<br>* modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.<br>|
| Active Comparator: INSURE<br>INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant. | Other: INSURE technique<br>* INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intubation rate |  | 100-days |
Study of the Effects of Carbohydrate Counting

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that non-optimally treated carbohydrate counting-naïve patients with type 1 diabetes can achieve better metabolic control by counting carbohydrates and that the metabolic control can be further improved with concurrent use of an integrated glucose meter and bolus calculator. The investigators want to test the hypothesis in this study.

Official Title
-----------------
The Effect of Carbohydrate Counting and Bolus Calculation Using an Electronic Calculator in Carbohydrate Counting-naïve Persons With Non-optimally Treated Type 1 Diabetes

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Other: Education
* Other: Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 diabetes Diabetes duration at least 12 months MDI therapy HbA1c 8-10,5% (both included) Exclusion Criteria: Gastroparesis Present or former practice of carbohydrate counting Pregnancy or nursing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>Participants in this arm continues their usual insulin therapy | |
| Active Comparator: Carb counting<br>Participants in this arm are taught carb counting | Other: Education<br>* Participants are taught the principles of carb counting<br>|
| Active Comparator: Carb counting and bolus calculator<br>Participants in this arm are taught carb counting and are provided with an integrated glucose meter and bolus calculator. | Other: Education<br>* Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.<br>* Other names: The integrated glucose meter and bolus calculator: Aviva Expert, Roche;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation in blood glucose | Measured by CGM | 4 months | 
| Number of hypoglycemic events | BG < or = 2.8 and/or unconsciousness | 4 months | 
| Treatment satisfaction | Questionnaires | 4 months | 
| Total daily insulin dose |  | 4 months | 
| Weight |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carbohydrate counting, Insulin bolus calculation
Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension

Study Overview
=================
Brief Summary
-----------------
Insulin resistance is a key mechanism in metabolic disorders, which has also been implicated in the development of pulmonary hypertension. In this pilot study, the investigators´ goal is to directly determine insulin sensitivity in idiopathic pulmonary arterial hypertension patients and to compare the results with data from healthy controls.

Official Title
-----------------
Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension - a Pilot Study

Conditions
-----------------
Insulin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signed informed consent form patients with idiopathic or hereditary pulmonary hypertension / healthy controls Exclusion Criteria: premenopausal women other relevant lung disease relevant left heart disease untreated systemic hypertension Diabetes mellitus pulmonary hypertension other than idiopathic or hereditary form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Idiopathic Pulmonary Arterial Hypertension patients<br>Blood sampling Insulin resistance-measurement | |
| Healthy controls<br>Blood sampling Insulin resistance-measurement | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin resistance | Determination of insulin sensitivity using hyperinsulinemic-euglycemic clamp technique | 1 day |
Warfarin - How Good Are we at Maintaining Target Range ?

Study Overview
=================
Brief Summary
-----------------
Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the real world for patients receiving Warfarin for lone atrial fibrillation.

Official Title
-----------------
Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prescription for Warfarin Atrial Fibrillation Exclusion Criteria: Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma. Conditions with increased risk of bleeding.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients receiving Warfarin<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding Complication | Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed. | 10 years | 
| Cardiovascular outcome | Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation, Warfarin, Safety
Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure

Study Overview
=================
Brief Summary
-----------------
Patients with CHF benefit from heart rate lowering, and the investigators have previously demonstrated that this does not adversely affect exercise tolerance. In a pacemaker population we also have shown that preventing heart rate lowering is detrimental in terms of symptoms and prognosis. The aim of the study is to therefore to establish whether heart rate limitation in patients with heart failure has a negative impact on exercise capacity. If the investigators establish that this is not the case, physicians will be able to confidently prescribe heart rate lowering agents, and programme pacemakers to allow bradycardia without the concern that there will be detrimental effects of symptom.

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Drug: ivabradine
* Drug: Placebo
* Other: Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to walk on a treadmill Able to provide consent Heart failure (or not) depending upon the arm. Patients with atrial fibrillation to have had an AV node ablation (or very slow response to AF) Exclusion Criteria: Cognitive impairment, known reaction to ivabradine, musculoskeletal issues limiting walking on a treadmill.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ivabradine<br>Exercise with ivabradine | Drug: ivabradine<br> <br> Other: Exercise<br> <br> |
| Placebo Comparator: Placebo<br>Exercise with placebo | Drug: Placebo<br> <br> Other: Exercise<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examining the effects of iatrogenic CI on exercise capacity | Each subject will undergo a full echocardiographic examination.We will assess LV systolic and diastolic function variables, mitral regurgitation, and pulmonary artery pressure. | 24 months |
A Comparative Study of Depth of Anesthesia Monitored by Bispectral Index (BIS) Values

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether induction of anesthesia with thiopental followed by propofol infusion is able to maintain sufficient depth of anesthesia .

Official Title
-----------------
A Comparative Study of Depth of Anesthesia Monitored by BIS Values in Two Anesthesia Techniques

Conditions
-----------------
Anesthetics

Intervention / Treatment
-----------------
* Drug: propofol
* Drug: thiopental,propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: being adult having ASA I or II scheduled for elective cataract surgery under general anesthesia Exclusion Criteria: massive obesity intake of any central nervous system (CNS) stimulants intake of CNS depressants intake of Tricyclic antidepressants known adverse reaction to the study drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: propofol-propofol<br> | Drug: propofol<br> <br> |
| Experimental: thiopental-propofol<br> | Drug: thiopental,propofol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
An Empirical Study of Perceived Hospital Service Quality: A Comparison of Inpatient, Outpatient and Emergence Patient

Study Overview
=================
Brief Summary
-----------------
The authors employ a questionary approach to understanding the relational among patients' perceptions of inpatient, outpatient and emergency room service and their overall perceptions of service quality, satisfaction with hospital.The questionary was applied in total 300 patients (100 inpatients, 100 outpatients and 100 emergency patients).

Official Title
-----------------
An Empirical Study of Perceived Hospital Service Quality: A Comparison of Inpatient, Outpatient and Emergence Patient

Conditions
-----------------
Service Quality, Satisfaction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who want to write our questionary. Exclusion Criteria: Patients who reject to write our questionary.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| inpatient<br> | |
| outpatient<br> | |
| emergency patient<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Effect of Patient Education on Opioid Consumption

Study Overview
=================
Brief Summary
-----------------
Prospective, randomized clinical trial investigating the use of patient education on post-operative narcotic consumption

Conditions
-----------------
Rotator Cuff Injury

Intervention / Treatment
-----------------
* Other: Formal education regarding opioid usage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over the age of 18 clinically indicated for an arthroscopic rotator cuff repair Exclusion Criteria: Patients with irreparable rotator cuff tears allergic or sensitivity to the study medication history of gastrointestinal issues any evidence of glenohumeral arthritis inability to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Normal pre-operative education<br>• Control group received normal pre-operative education regarding surgery | |
| Active Comparator: Opioid usage education<br>• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction | Other: Formal education regarding opioid usage<br>* Participannts watched a 2 minute video and were given educational materials<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Opioid Usage | count of total narcotic pills not taken by patients | 3 months |